EP2763540A4 - Compositions and methods for assessing and treating inflammatory diseases and disorders - Google Patents

Compositions and methods for assessing and treating inflammatory diseases and disorders

Info

Publication number
EP2763540A4
EP2763540A4 EP12829361.0A EP12829361A EP2763540A4 EP 2763540 A4 EP2763540 A4 EP 2763540A4 EP 12829361 A EP12829361 A EP 12829361A EP 2763540 A4 EP2763540 A4 EP 2763540A4
Authority
EP
European Patent Office
Prior art keywords
assessing
disorders
compositions
methods
inflammatory diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP12829361.0A
Other languages
German (de)
French (fr)
Other versions
EP2763540A1 (en
Inventor
Eran Elinav
Richard A Flavell
Till Strowig
Jorge H Mejia
Chengcheng Jin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yale University
Original Assignee
Yale University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yale University filed Critical Yale University
Publication of EP2763540A1 publication Critical patent/EP2763540A1/en
Publication of EP2763540A4 publication Critical patent/EP2763540A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6869—Methods for sequencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
EP12829361.0A 2011-09-09 2012-04-16 Compositions and methods for assessing and treating inflammatory diseases and disorders Withdrawn EP2763540A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161532902P 2011-09-09 2011-09-09
US201261584988P 2012-01-10 2012-01-10
PCT/US2012/033753 WO2013036290A1 (en) 2011-09-09 2012-04-16 Compositions and methods for assessing and treating inflammatory diseases and disorders

Publications (2)

Publication Number Publication Date
EP2763540A1 EP2763540A1 (en) 2014-08-13
EP2763540A4 true EP2763540A4 (en) 2015-04-22

Family

ID=47832488

Family Applications (1)

Application Number Title Priority Date Filing Date
EP12829361.0A Withdrawn EP2763540A4 (en) 2011-09-09 2012-04-16 Compositions and methods for assessing and treating inflammatory diseases and disorders

Country Status (2)

Country Link
EP (1) EP2763540A4 (en)
WO (1) WO2013036290A1 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011503104A (en) 2007-11-09 2011-01-27 カリフォルニア インスティテュート オブ テクノロジー Immunomodulatory compounds and related compositions and methods
EP2555753B1 (en) 2010-04-07 2018-08-01 California Institute of Technology Vehicle for delivering a compound to a mucous membrane and related compositions, methods and systems
US9539281B2 (en) 2011-07-12 2017-01-10 The Brigham And Women's Hospital, Inc. Lipid-containing PSA compositions, methods of isolation and methods of use thereof
IN2015DN03796A (en) * 2012-10-17 2015-10-02 Enterome
US9758838B2 (en) 2013-03-12 2017-09-12 Yale University Compositions and methods for identifying secretory antibody-bound microbes
WO2014182966A1 (en) * 2013-05-10 2014-11-13 California Institute Of Technology Probiotic prevention and treatment of colon cancer
US10920283B2 (en) 2013-11-01 2021-02-16 Washington University Methods to establish and restore normal gut microbiota function of subject in need thereof
FI127671B (en) 2014-05-28 2018-11-30 Filip Scheperjans Method for diagnostics of Parkinson’s disease
WO2016033439A2 (en) 2014-08-28 2016-03-03 Yale University Compositions and methods for the treating an inflammatory disease or disorder
US9968616B2 (en) 2014-10-25 2018-05-15 The Chinese University Of Hong Kong Discovery of FDA-approved drugs as inhibitors of fatty acid binding protein 4 using molecular docking screening
WO2016126831A1 (en) * 2015-02-03 2016-08-11 Mayo Foundation For Medical Education And Research Methods and materials for assessing and treating arthritis
WO2016201342A1 (en) 2015-06-10 2016-12-15 California Institute Of Technology Sepsis treatment and related compositions methods and systems
CA2997211A1 (en) 2015-08-19 2017-02-23 President And Fellows Of Harvard College Lipidated psa compositions and methods
WO2018014012A1 (en) 2016-07-15 2018-01-18 President And Fellows Of Harvard College Glycolipid compositions and methods of use
US11359246B2 (en) 2020-06-22 2022-06-14 Regeneron Pharmaceuticals, Inc. Treatment of obesity with G-protein coupled receptor 75 (GPR75) inhibitors

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004045525A2 (en) * 2002-11-15 2004-06-03 Morehouse School Of Medicine Anti-chemokine and associated receptor antibodies and uses for inhibition of inflammation.
WO2005016226A2 (en) * 2003-08-14 2005-02-24 Hadasit Medical Research Services & Development Ltd. Pharmaceutical compositions comprising ccr5 antagonists
WO2011043654A1 (en) * 2009-10-05 2011-04-14 Aak Patent B.V. Methods for diagnosing irritable bowel syndrome
WO2011082218A1 (en) * 2009-12-31 2011-07-07 Ira Milton Trachtman Compositions and method for treatment and prophylaxis of inflammatory bowel disease

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4160452A (en) 1977-04-07 1979-07-10 Alza Corporation Osmotic system having laminated wall comprising semipermeable lamina and microporous lamina
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
US5023243A (en) 1981-10-23 1991-06-11 Molecular Biosystems, Inc. Oligonucleotide therapeutic agent and method of making same
US5190931A (en) 1983-10-20 1993-03-02 The Research Foundation Of State University Of New York Regulation of gene expression by employing translational inhibition of MRNA utilizing interfering complementary MRNA
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
US5168053A (en) 1989-03-24 1992-12-01 Yale University Cleavage of targeted RNA by RNAase P
US5459039A (en) 1989-05-12 1995-10-17 Duke University Methods for mapping genetic mutations
US5424186A (en) 1989-06-07 1995-06-13 Affymax Technologies N.V. Very large scale immobilized polymer synthesis
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5288644A (en) 1990-04-04 1994-02-22 The Rockefeller University Instrument and method for the sequencing of genome
EP1046421B8 (en) 1990-12-06 2006-01-11 Affymetrix, Inc. (a Delaware Corporation) Methods and reagents for very large scale immobilized polymer synthesis
US5384261A (en) 1991-11-22 1995-01-24 Affymax Technologies N.V. Very large scale immobilized polymer synthesis using mechanically directed flow paths
DE69433180T2 (en) 1993-10-26 2004-06-24 Affymetrix, Inc., Santa Clara FIELDS OF NUCLEIC ACID PROBE ON ORGANIC CHIPS
US6270974B1 (en) 1998-03-13 2001-08-07 Promega Corporation Exogenous nucleic acid detection
US6159693A (en) 1998-03-13 2000-12-12 Promega Corporation Nucleic acid detection
CA2587670A1 (en) * 2004-11-01 2006-05-11 George Mason University Compositions and methods for diagnosing colon disorders
EP2398479A2 (en) * 2009-02-19 2011-12-28 Galapagos N.V. Methods for identifying and compounds useful for the diagnosis and treatment of diseases involving inflammation
BR112012004387A2 (en) * 2009-08-28 2015-09-08 Vlst Corp anticin antibodies that bind to multiple cc chemokines.

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004045525A2 (en) * 2002-11-15 2004-06-03 Morehouse School Of Medicine Anti-chemokine and associated receptor antibodies and uses for inhibition of inflammation.
WO2005016226A2 (en) * 2003-08-14 2005-02-24 Hadasit Medical Research Services & Development Ltd. Pharmaceutical compositions comprising ccr5 antagonists
WO2011043654A1 (en) * 2009-10-05 2011-04-14 Aak Patent B.V. Methods for diagnosing irritable bowel syndrome
WO2011082218A1 (en) * 2009-12-31 2011-07-07 Ira Milton Trachtman Compositions and method for treatment and prophylaxis of inflammatory bowel disease

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DELPHINE M SAULNIER ET AL: "Gastrointestinal Microbiome Signatures of Pediatric Patients With Irritable Bowel Syndrome", GASTROENTEROLOGY, ELSEVIER, PHILADELPHIA, PA, vol. 141, no. 5, 24 June 2011 (2011-06-24), pages 1782 - 1791, XP028325678, ISSN: 0016-5085, [retrieved on 20110708], DOI: 10.1053/J.GASTRO.2011.06.072 *
ERAN ELINAV ET AL: "NLRP6 Inflammasome Regulates Colonic Microbial Ecology and Risk for Colitis", CELL, CELL PRESS, US, vol. 145, no. 5, 22 April 2011 (2011-04-22), pages 745 - 757, XP028221175, ISSN: 0092-8674, [retrieved on 20110502], DOI: 10.1016/J.CELL.2011.04.022 *
See also references of WO2013036290A1 *
YANFEI CHEN ET AL: "Characterization of fecal microbial communities in patients with liver cirrhosis", HEPATOLOGY, vol. 54, no. 2, 26 June 2011 (2011-06-26), pages 562 - 572, XP055159513, ISSN: 0270-9139, DOI: 10.1002/hep.24423 *
YOUNES J. ERRAHALI ET AL: "CCL26-Targeted siRNA Treatment of Alveolar Type II Cells Decreases Expression of CCR3-Binding Chemokines and Reduces Eosinophil Migration: Implications in Asthma Therapy", JOURNAL OF INTERFERON & CYTOKINE RESEARCH, vol. 29, no. 4, 1 April 2009 (2009-04-01), pages 227 - 239, XP055175655, ISSN: 1079-9907, DOI: 10.1089/jir.2008.0051 *

Also Published As

Publication number Publication date
EP2763540A1 (en) 2014-08-13
WO2013036290A1 (en) 2013-03-14

Similar Documents

Publication Publication Date Title
IL260585B (en) Compositions and methods for treating retinal diseases
EP2763540A4 (en) Compositions and methods for assessing and treating inflammatory diseases and disorders
ZA201305784B (en) Compositions and methods for treating chronic inflammation and inflammatory diseases
EP2684167A4 (en) Compositions and methods useful for treating diseases
ZA201304334B (en) Methods for diagnosing and treating eye-length related disorders
IL228030A0 (en) Methods and compositions for treating hyperuricemia and metabolic disorders associated with hyperuricemia
DK3292875T3 (en) Compositions and methods for treating diseases
HK1213912A1 (en) Methods and compositions for treating multiple sclerosis and related disorders
EP2691529A4 (en) Methods and compositions for treating brain diseases
ZA201203002B (en) Compositions and methods for treating inflammatory disorders
EP2544703A4 (en) Methods of treating vascular inflammatory disorders
WO2011112588A9 (en) Compositions and methods for treating inflammatory disorders
HK1202248A1 (en) Compositions and methods for treating neurodegenerative disease
EP2782566A4 (en) L-serine compositions, methods and uses for treating neurodegenerative diseases and disorders
IL232190A0 (en) Methods of treating inflammatory disorders using anti-m-csf antibodies
HK1202246A1 (en) Compositions and methods for treating neurodegenerative disease
EP2741771A4 (en) Methods and compositions for the treatment of autoimmune and inflammatory diseases
EP2575799A4 (en) Methods for treating inflammatory autoimmune disorders
EP2780360A4 (en) Compositions and methods for treating autoimmune and inflammatory disorders
EP2643470A4 (en) Compositions and methods for diagnosing and treating diseases and disorders associated with d-dt
EP2624844A4 (en) Methods and compositions using anti-lps ligands for the treatment and prevention of inflammatory disorders
IL223385B (en) Treatment of inflammatory disorders
EP2673372A4 (en) Methods of prognosing and administering treatment for inflammatory disorders
EP2600864A4 (en) Compositions and methods for treating inflammatory diseases
EP2718427A4 (en) Compositions and methods for glioblastoma treatment

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20140409

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

RA4 Supplementary search report drawn up and despatched (corrected)

Effective date: 20150319

RIC1 Information provided on ipc code assigned before grant

Ipc: A01N 63/00 20060101AFI20150313BHEP

17Q First examination report despatched

Effective date: 20160420

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20170315

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20170726